Nab-Xelpac100 mg/vial

Nab-Xelpac is a cytotoxic chemotherapy agent administered by an oncologist in a hospital or cancer-center infusion setting. Its indications are classified below by strength of evidence.

Established / FDA-approved indications

• Metastatic breast cancer (single agent): after failure of combination chemotherapy for metastatic disease, or relapse within 6 months of adjuvant chemotherapy; prior therapy should generally have included an anthracycline unless clinically contraindicated.
• Locally advanced or metastatic non-small cell lung cancer (NSCLC): first-line treatment, used in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
• Metastatic adenocarcinoma of the pancreas: first-line treatment, used in combination with gemcitabine.

Off-label use (not FDA-approved, used based on limited evidence/guideline discretion)

• Advanced epithelial ovarian cancer and other solid tumors where taxane-based therapy is indicated, at the treating oncologist's discretion.

Nab-Xelpac is never a first-choice, self-selected medicine; the treating oncologist determines whether it is appropriate for a given cancer type, stage, and combination regimen.

Each single-use vial contains lyophilized Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] powder for reconstitution, in which paclitaxel is bound to human albumin in nanoparticle form (no Cremophor EL or other solvent is used in this formulation, unlike conventional solvent-based paclitaxel).

Common vial strength: 100 mg paclitaxel per vial (as albumin-bound nanoparticles), for reconstitution and intravenous infusion.

Nab-Xelpac is a taxane-class, microtubule-stabilizing cytotoxic chemotherapy agent in which paclitaxel is formulated as albumin-bound nanoparticles. This nanoparticle-albumin technology improves paclitaxel's solubility and delivery, and removes the need for the solvent (Cremophor EL) used in conventional paclitaxel, which in turn reduces the need for routine premedication with corticosteroids and antihistamines that solvent-based paclitaxel requires.

Nab-Xelpac is supplied as a lyophilized powder that must be reconstituted and administered as an intravenous infusion strictly under oncology specialist supervision in a hospital or cancer-treatment-center setting; it is not a self-administered medicine.

Nab-Xelpac belongs to the taxane class of antineoplastic (anti-cancer) agents, more specifically classified as an antimicrotubule / mitotic inhibitor cytotoxic chemotherapy drug.

Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] works by binding to beta-tubulin subunits within microtubules, promoting microtubule assembly from tubulin dimers and stabilizing the resulting microtubules against depolymerization. This abnormal stabilization disrupts the normal dynamic reorganization of the microtubule network that is essential for mitosis and interphase cellular functions, arresting cells in the G2/M phase of the cell cycle and ultimately triggering apoptosis (programmed cell death) of rapidly dividing tumor cells.

The albumin-nanoparticle formulation of Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] exploits albumin-receptor (gp60)-mediated transcytosis and albumin-binding protein (SPARC) interactions in the tumor microenvironment, which is believed to enhance drug delivery and intratumoral accumulation compared with conventional solvent-based paclitaxel, while avoiding solvent-related hypersensitivity reactions.

Following intravenous infusion, paclitaxel from Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] is extensively protein-bound, undergoes hepatic metabolism (largely via CYP2C8 and CYP3A4), and is eliminated mainly through biliary/fecal excretion.

Nab-Xelpac is given strictly as an intravenous (IV) infusion in a hospital or oncology infusion center, through a properly functioning IV line, over the time specified for the indication being treated (approximately 30 to 40 minutes, depending on the regimen). It must never be given as a bolus injection, and it is never taken orally or self-administered at home.

Trained oncology nursing staff monitor the patient during and after each infusion of Nab-Xelpac for infusion-related reactions, and vital signs are checked at intervals per institutional chemotherapy-administration protocol.

Clinically significant drug interactions with Nab-Xelpac include the following:

• CYP2C8 and CYP3A4 inhibitors/inducers (e.g., ketoconazole and other strong CYP3A4 inhibitors, or strong CYP3A4/CYP2C8 inducers such as rifampin): may alter paclitaxel metabolism and increase toxicity or reduce efficacy; concomitant use requires caution and close monitoring.
• Other myelosuppressive agents or radiation therapy: concurrent use increases the risk of additive bone marrow suppression (neutropenia, thrombocytopenia, anemia); blood counts must be monitored closely.
• Sequence with platinum agents (e.g., carboplatin) or gemcitabine: when used in approved combination regimens, Nab-Xelpac is given before the platinum agent or before gemcitabine, per the specific protocol sequence, to maintain the established efficacy and toxicity profile.

Patients should inform their oncology team of all other medicines, herbal products, and supplements being taken before each cycle of Nab-Xelpac.

Side effects of Nab-Xelpac are common given its cytotoxic mechanism and are monitored closely by the oncology team throughout treatment.

Very common

• Alopecia (hair loss)
• Neutropenia, anemia, thrombocytopenia (see Precautions for myelosuppression monitoring)
• Peripheral neuropathy (numbness, tingling in hands/feet; see Precautions)
• Fatigue and asthenia
• Nausea, vomiting, diarrhea
• Myalgia and arthralgia
• Elevated liver enzymes

Less common but clinically important

• Infections related to neutropenia
• Mucositis/stomatitis
• Peripheral edema
• Hypersensitivity reactions (usually mild given the absence of solvent; see Precautions)
• Cardiac arrhythmias (uncommon)

Nab-Xelpac is contraindicated in pregnancy because it is a cytotoxic agent with demonstrated teratogenic and embryo-fetal toxicity potential in animal studies; it must not be given to a pregnant patient, and women of reproductive potential should use effective contraception during and for a period after treatment.

It is not known whether paclitaxel from Nab-Xelpac passes into breast milk; because of the potential for serious adverse effects in a breastfeeding infant, breastfeeding is not recommended during treatment with Nab-Xelpac and for a period after the last dose, on the physician's advice.

Treatment with Nab-Xelpac requires close oncology supervision because of the following important risks:

• Myelosuppression/neutropenia: Bone marrow suppression, particularly neutropenia, is dose-dependent and common; complete blood counts must be monitored before each cycle, and doses withheld or reduced for significant neutropenia or thrombocytopenia.
• Peripheral neuropathy: Sensory neuropathy is common and dose-limiting; it may require dose reduction, delay, or discontinuation if it becomes severe.
• Hypersensitivity reactions: Although less frequent than with solvent-based paclitaxel, hypersensitivity reactions (including rash, flushing, dyspnea, hypotension) can occur and require prompt management; severe reactions warrant discontinuation.
• Hepatic impairment: Patients with hepatic impairment require dose adjustment of Nab-Xelpac, as reduced clearance increases toxicity risk; liver function should be assessed before each cycle.
• Sepsis and infection: Neutropenia-related infections, including sepsis, have been reported and require prompt evaluation and treatment.
• Embryo-fetal toxicity: see Pregnancy and Lactation.

There is no known specific antidote for Nab-Xelpac overdosage. Because Nab-Xelpac is administered under direct medical supervision with calculated, weight/BSA-based dosing, accidental overdose is uncommon but would be expected to manifest as exaggerated bone marrow suppression, severe mucositis, and peripheral neuropathy.

Any suspected overdose of Nab-Xelpac is a medical emergency requiring immediate hospital-based supportive care (e.g., growth factor support, blood product transfusion, antibiotics for infection) under close monitoring; patients or caregivers should contact the treating hospital or emergency services immediately rather than attempting any home treatment.

Store unopened vials of Nab-Xelpac at room temperature (below 30°C), in the original carton to protect from light. Reconstituted suspension should be used promptly per hospital pharmacy protocol and stored under refrigeration only for the limited time specified by the manufacturer if not used immediately. Keep out of reach of children, and dispose of as cytotoxic pharmaceutical waste per institutional policy.

Pediatric use: Safety and efficacy of Nab-Xelpac have not been established in children; it is not routinely used in pediatric oncology outside of specialist protocols.

Elderly: Patients above 65 years may have an increased risk of certain toxicities, particularly peripheral neuropathy and myelosuppression; no specific dose reduction is mandated solely for age, but closer monitoring is advised.

Hepatic impairment: Requires dose adjustment (see Precautions and Warnings) due to reduced drug clearance.

Renal impairment: Formal dose-adjustment data are limited; Nab-Xelpac is used with caution and close monitoring in patients with significant renal impairment.

The duration of treatment with Nab-Xelpac is determined by the treating oncologist based on tumor response, cycle-by-cycle blood counts and tolerance, and the specific protocol (e.g., repeated 21-day or 28-day cycles), and is continued until disease progression, unacceptable toxicity, or completion of the planned treatment course.

Nab-Xelpac is supplied as a lyophilized powder in single-use vials that must be reconstituted before use, by trained pharmacy or oncology personnel under aseptic conditions.

• Reconstitute with the manufacturer-specified volume of 0.9% Sodium Chloride Injection to achieve a final concentration of approximately 5 mg/mL paclitaxel.
• Gently invert the vial for at least 1 minute to fully wet the lyophilized cake; avoid forceful shaking, which can cause excessive foaming.
• Allow the reconstituted suspension to stand for a few minutes so that foam can dissipate before withdrawing the dose.
• Inspect the reconstituted suspension visually for particulate matter before administration; use promptly per institutional protocol.

Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] is classified as an antineoplastic agent, specifically a taxane / antimicrotubule mitotic inhibitor, formulated using albumin-bound nanoparticle drug-delivery technology.

Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] acts by binding beta-tubulin and stabilizing microtubules against depolymerization, disrupting the normal dynamic assembly/disassembly of the mitotic spindle. This arrests susceptible tumor cells in the G2/M phase of the cell cycle and promotes apoptosis; the albumin-nanoparticle carrier is thought to enhance tumor drug delivery via albumin-receptor-mediated pathways while avoiding the solvent used in conventional paclitaxel formulations.

D

The safety and efficacy of Nab-Xelpac in pediatric patients have not been established. Its use in children is limited to specialized pediatric oncology protocols under expert supervision, outside of the drug's standard approved adult indications.